|
Jan 31
|
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
|
|
Jan 31
|
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
|
|
Jan 29
|
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
|
|
Jan 28
|
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
|
|
Jan 27
|
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
|
|
Oct 14
|
ENHERTU gains conditional approval in China to treat NSCLC
|
|
Jun 24
|
Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan
|
|
Feb 19
|
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
|
|
Feb 16
|
Daiichi invests 1 bln eur near Munich to make precision cancer drugs
|
|
Jan 8
|
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
|
|
Jan 4
|
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
|
|
Jan 3
|
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
|
|
Dec 26
|
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
|
|
Dec 22
|
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
|
|
Dec 18
|
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
|
|
Nov 27
|
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo
|
|
Nov 9
|
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
|
|
Sep 11
|
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
|
|
Sep 10
|
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
|
|
Sep 10
|
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
|